Jonathan Goodman, MPhil, Author at Oncology Nurse Advisor https://www.oncologynurseadvisor.com Mon, 04 Mar 2024 15:37:41 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png Jonathan Goodman, MPhil, Author at Oncology Nurse Advisor https://www.oncologynurseadvisor.com 32 32 Social Support Appears to Affect HRQoL Among Patients With Multiple Myeloma https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/multiple-myeloma-social-support-health-quality-life-treatment-risk/ Mon, 04 Mar 2024 14:10:00 +0000 https://www.oncologynurseadvisor.com/?p=116906 Maternal Exposure to Anticancer Drugs May Increase Risk for Pediatric Leukemia https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/pediatric-cancer-maternal-exposure-anti-cancer-drugs-increase-risk/ Thu, 22 Feb 2024 14:10:00 +0000 https://www.oncologynurseadvisor.com/?p=116828 Frontline Tazemetostat May Induce Complete Metabolic Response in FL https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/follicular-lymphoma-frontline-tazemotostat-induce-metabolic-response-treatment/ Tue, 16 Jan 2024 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=116035 High-Dose Cytarabine, With or Without Vorinostat, Does Not Improve Outcomes in AML https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/acute-myeloid-leukemia-aml-high-dose-cytarabine-vorinostat-treatment/ Mon, 18 Dec 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=114978 Immunotherapy Increasingly Used in Cancer CareResearchers sought to determine whether high-dose cytarabine, with or without vorinostat, is superior to standard cytarabine in previously untreated AML.]]> 10-Day Decitabine Regimen May Be Less Toxic Than Chemotherapy Among Older Patients With AML https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/acute-myeloid-leukemia-aml-decitabine-regimen-less-toxic-chemotherapy/ Mon, 04 Dec 2023 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=114584 Nurse talking to elderly patient.Researchers sought to determine whether a 10-day decitabine regimen would have a better safety profile among older patients with AML.]]> Combination Ibrutinib Plus Venetoclax Improves Outcomes Compared With Chemoimmunotherapy in CLL https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/chronic-leukemia-cll-ibrutinib-venetoclax-improves-outcomes-treatment-risk/ Fri, 01 Dec 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=114493 Venetoclax and ibrutinib are therapeutic agents for CLL.Researchers sought to determine whether combination ibrutinib plus venetoclax would improve survival in patients with previously untreated CLL.]]> Some Patients With iNHL, MM May View Costs of Care as Most Important Factors  https://www.oncologynurseadvisor.com/home/cancer-types/hematologic-cancers/inhl-lymphoma-multiple-myeloma-costs-care-treatment-risk-patients/ Tue, 28 Nov 2023 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=114415 The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.Researchers sought to determine how patients and caregivers rate different factors of clinical care in the iNHL and MM settings.]]> Younger Patients With Relapsed or Refractory DLBCL Have Poor Survival Rates https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/young-patients-dlbcl-lymphoma-poor-survival-treatment-risk/ Wed, 15 Nov 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=114183 A doctor speaks with a female teenage patient.Researchers sought to determine clinical outcomes among AYAs diagnosed with DLBCL.]]> Adding Zanubrutinib to Obinutuzumab Improves PFS in Relapsed/Refractory FL https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/lymphoma-treatment-risk-zanubrutinib-obinutuzumab-survival-pfs/ Tue, 07 Nov 2023 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=113976 Researchers sought to determine the safety and efficacy of combination zanubrutinib plus obinutuzumab in patients with relapsed/refractory FL.]]> Adding Daratumumab to RVd Improves PFS in Transplant-Eligible MM https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/multiple-myeloma-daratumumab-rvd-improves-survival-treatment-risk/ Tue, 31 Oct 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=113811 Doctor talking to patient.Researchers sought to determine whether adding daratumumab to RVd would improve responses and survival in patients with transplant-eligible multiple myeloma.]]>